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Objectives: To access the cost-effectiveness of two common strategies and 
alternative triage strategy for patients with stage IB cervical cancer. MethOds: 
A Markov state transition model was constructed to compare three strategies: (1) 
radical hysterectomy followed by tailored adjuvant therapy (RH+TA); (2) primary 
chemoradiation (pCCRT); (3) Triage strategy, in which patients without risk in pre-
operative MRI undergo primary surgery and those with any risk factors in MRI 
undergo primary CCRT. All relevant literatures were identified to extract the prob-
ability data. Direct medical costs were estimated from Korean National Health 
Insurance database. Strategies were compared using incremental cost per year of 
life saved (YLS). Results: RH+TA strategy was the least expensive strategy. 
Although pCCRT strategy had similar outcomes, pCCRT strategy was more expen-
sive than RH+TA ($10,945 vs. $7,257). A sensitivity analysis showed that RH+TA is 
cost-effective than pCCRT when the percentage of patients who require no adjuvant 
therapy after radical hysterectomy exceeds 30%. Triage strategy was more expensive 
and more effective, with an incremental cost-effectiveness ratio (ICER) of $39,271 per 
year of life saved (YLS) compared to RH+TA. Results are relatively sensitive to variation 
in how the rate of patients who require adjuvant therapy after surgery decrease in 
MRI-based strategy. cOnclusiOns: RH+TA is cost-effective than pCCRT in Stage IB 
cervical cancer. Given the current high rates of adjuvant therapy after primary radical 
surgery in Stage IB cervical cancer, MRI-based strategy has potential to be cost-effective 
when compared to RH+TA at high test performance and at the lower range of test costs.
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Objectives: To assess costs and cost effectiveness of CTC compared with BE in patients 
with symptomatic colorectal cancers from the UK NHS perspective. MethOds: A 
Markov model with Monte Carlo simulation was developed to assess the costs, life years 
and quality adjusted life years associated with CTC vs. BE in patients with symptoms 
suggestive of bowel cancer.  The initial diagnostic findings, follow up investigations for 
suspected colonic lesions, confirmed diagnoses, and resources used were estimated 
from individual patient data from the SIGGAR trial. We extrapolated the trial results 
over a patient’s life time. Transition probabilities among small polyps, large polyps and 
different stages of cancer, and the costs and utilities associated with each state, were 
derived from the literature. Outcomes were measured as incremental cost per life year 
saved and incremental cost per quality adjusted life year (QLAY) gained. Probabilistic 
sensitivity analysis was conducted across key input values. Results: The Mean life 
time costs required to reach a diagnosis were £658 and £718 for BE and CTC trial arms 
respectively leading to a mean difference of £61 for each patient having a diagnostic 
test. The (discounted) life years obtained were 9.943 and 9.975, and (discounted) QALYs 
were 8.900 and 8.938 for BE and CTC respectively leading to 0.032 life years, 0.038 QALYs 
advantaged for CTC. The incremental costs per life year gained was £1,856 (£1,133 with-
out discounting), and per QALYs gained at £1,598 (£969 without discounting) for CTC 
compared with BE. The probabilistic sensitivity analysis produced that the probability 
of CTC being cost effective was 75% at a willingness-to pay value of £20,000 for a QALY 
gained. cOnclusiOns: This analysis showed that CTC was clearly cost effective over 
BE.  Therefore CTC should be recommended in place of BE as one of the primary diag-
nostic methods for patients referred with symptoms suggestive of colorectal cancer.
CN3
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Objectives: Crizotinib, a first-in-class compound that specifically inhibits a tumor-
specific protein called anaplastic lymphoma kinase (ALK) of non-small-cell lung cancer 
(NSCLC) is currently not reimbursable to all Thai patients. This budget impact analysis 
was aimed at examining the financial impact if crizotinib was subsidized for all identi-
fied ALK+ NSCLC patients in Thailand. MethOds: A 3-year budget impact model is 
designed to capture differences in outcomes related to the overall direct costs incurred 
from receiving crizotinib versus other standard therapies for 1st, 2nd and 3rd lines of care. 
Local incidence of NSCLC and ALK+ rate were estimated from the national registry data 
and Chiang Mai University (CMU) Hospital data. The government procurement data-
base was the reference for the drug cost. Other specific medical costs came from CMU 
Hospital. Cost attributable to prerequisite diagnostic testing was also incorporated into 
the model and testing strategies were created according to standard practice. Results: 
An estimated 5,377 new cases were diagnosed as advanced NSCLC annually and referred 
for further testing prior to receiving therapy. The net budget impact was estimated under 
two scenarios. In the first scenario where crizotinib was subsidized with no restriction, 
the average net budgetary impact in the 3-year period was 576 million baht (US$18 
million) from the average 414 patients receiving crizotinib yearly. The second scenario 
in where crizotinib was restrictively used as 2nd or 3rd line, the average 3-year financial 
difference was 284 million baht (US$8.9 million) from the average 214 patients receiving 
crizotinib yearly. Univariate sensitivity analysis showed that crizotinib acquisition cost 
and prevalence of ALK+ were the leading parameters influencing the results of the first 
and second scenarios, respectively. cOnclusiOns: This model captured the clinical 
and economic values of crizotinib for ALK+ NSCLC patients in Thailand. Nevertheless, 
humanistic value should be taken into account and still needs to be explored.
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Yong M1, Xianjun X2, Jinghu L2, Jie Z2, Yunyun F1
1Beijing University of Chinese Medicine, Beijing, China, 2China Health Insurance Research 
Association, Beijing, China
Objectives: By estimating the direct medical cost of malignant neoplasms 
inpatients with urban basic health insurance scheme(UBHIS) in 2011 in China, 
we try to provide evidence for the government to manage the illness more effec-
tively. MethOds: A nationwide, cross-sectional sampling of malignant neoplasms 
inpatients with UBHIS was extracted from the China Health Insurance Research 
Association claim database. A retrospective analysis was adopted and all results 
were extrapolated to the whole country according to the scale of the population, 
economics and other factors in the sample cities. Results: The visits of malignant 
neoplasms inpatients, accounted for 7.64% of total visits, were 2.92 million. The 
rank of main malignant neoplasms inpatients  were lung cancer, breast cancer, 
gastric cancer, rectum cancer, colon cancer and liver cancer, which accounted for 
54.09% in all malignant neoplasms inpatients. The  hospitalization expenses of 
malignant neoplasms inpatients was 42.61 billion yuan, as the top costs, which 
accounted for 13.59% in all hospitalization expenses; the proportion of the above six 
kinds of cancer costs was 52.00% (22.16 billion yuan) in all hospitalization expenses 
of malignant neoplasms inpatients. The average hospitalization expenses of each 
visit was 14,594 yuan (14,513 yuan in 2010), the average hospitalization expenses 
of  every day was 914 yuan (increasing by 8.7% from 2010). The composition of 
hospitalization expenses: drugs 53.85%, diagnosis and treatments 39.00%, medi-
cal consumables 7.15%. Reimbursement by UBHIS was 69.34% (66.44% in 2010), 
about 29.55 billion yuan. cOnclusiOns: Cancer brought large disease burden in 
China, particularly, six kinds of cancer mentioned above have much hospitalization 
expenses. The reimbursement by UBHIS added 3% from 2010 to 2011, reducing the 
economic burden of malignant neoplasms inpatients. However, for the poor, the 
personal burden is still a problem. China has launched supplemental insurance 
for catastrophic health expenditure, relieving the burden of disease constantly.
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